Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Chiba, Urayasu, Japan Clinical Trials

A listing of Chiba, Urayasu, Japan clinical trials actively recruiting patients volunteers.

RESULTS

Found (50) clinical trials

A Phase 1/2 Study of TAK-788 in Japanese Patients

The drug being tested in this study is called TAK-788. TAK-788 is being tested to treat Japanese participants with NSCLC. This study has two parts (Phase 1 part and Phase 2 part), Phase 1 part of this study will look at the safety, efficacy, tolerability and PK of TAK-788 orally ...

Phase

4.93 miles

Learn More »

A Study of E7130 in Participants With Solid Tumors

The primary objective of this study is to evaluate the tolerability and safety profile of E7130 in participants with advanced solid tumors.

Phase

4.93 miles

Learn More »

A Study of MORAb-202 in Participants With Solid Tumors

The primary objective of this study is to evaluate the tolerability and safety profile of MORAb-202 in participants with solid tumors.

Phase

4.93 miles

Learn More »

Study of E7389 Liposomal Formulation in Subjects With Solid Tumor

The maximum tolerated dose (MTD) of E7389 liposomal formulation (E7389-LF) will be determined in the dose escalation part. Safety, pharmacokinetics (PK) and efficacy will be assessed using treatment regimen evaluated in dose escalation part in participants with breast cancer in the expansion part 1 and in participants with adenoid cystic ...

Phase

4.94 miles

Learn More »

Study of JNJ-61186372 a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer

This open label (all participants know the identity of the study drug), multicenter (more than one study site), first-in-human study consists of 2 parts. Part 1 is a JNJ-61186372 Monotherapy and Combination Dose Escalations and Part 2 JNJ-61186372 Monotherapy and Combination Dose Expansions. In Part 1, participants with evaluable NSCLC ...

Phase

6.14 miles

Learn More »

Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers

To characterize the safety and tolerability, identify recommended doses and regimens for future studies, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of LSZ102 as a single agent and in combination with either LEE011 or BYL719 in adult patients with locally advanced or metastatic ER+ breast cancer who have progressed after ...

Phase

6.14 miles

Learn More »

A Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas

Parts A and B will consist of 3 periods: Screening, Treatment and Follow-up. Screening Period: The Screening Period starts 28 days ( 3 days) prior to first dose of CC-90010. The informed document (ICD) must be signed and dated by the subject and the administering staff prior to the start ...

Phase

6.14 miles

Learn More »

U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer

This study has two parts: dose escalation and dose expansion. The primary objectives are: For Dose Escalation, to assess the safety and tolerability of U3-1402 in the study population and to determine the recommended dose for expansion of U3-1402 in the study population For Dose Expansion, to investigate the antitumor ...

Phase

6.14 miles

Learn More »

A Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102)

The purpose of this study is to evaluate the safety and tolerability of pemigatinib in Japanese subjects with advanced malignancies.

Phase

6.14 miles

Learn More »

Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors

This study will initially treat up to approximately 300 patients with advanced solid tumors at approximately 30 sites, worldwide. The study will be composed of a dose-limiting toxicity (DLT) assessment phase (Part A) and an expansion phase (Part B).

Phase

6.14 miles

Learn More »